By Fineline Cube 
China-based Akeso Biopharma (HKG: 9926) announced that the first patient has been enrolled in the phase 3 AK112-311/HARMONi-9 trial of ivonescimab for consolidation therapy in patients with limited-stage small cell lung carcinoma (LS-SCLC). The trial targets patients who have not progressed after standard concurrent chemoradiotherapy (cCRT).
Drug Profile
Ivonescimab is a PD-1/VEGF bispecific antibody. It was first approved by China’s National Medical Products Administration (NMPA) in May 2024 for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) that progressed after EGFR-TKI treatment. In April 2025, it received additional approval as a first-line monotherapy for advanced NSCLC with positive PD-L1 expression.-Fineline Info & Tech